# 10x Genomics Inc. (TXG)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $3.58B  
**Price:** $28.73 (-1.31%)

> 10x Genomics develops and sells instruments, consumables, and software for analyzing biological systems globally. The company specializes in single cell and spatial biology, enabling researchers to study individual cells and understand complex biological processes at unprecedented resolution. Its primary platforms include Chromium for single cell analysis, which provides transcriptomics, genomics, and epigenomics capabilities, and Visium for spatial gene expression analysis. Additionally, the company offers Xenium, an advanced spatial platform enabling simultaneous RNA and protein detection within tissue samples. 10x Genomics serves academic researchers, biopharmaceutical companies, and translational research institutions across the Americas, Europe, Middle East, Africa, China, and Asia Pacific. The company supports its platforms with integrated software solutions and supplies the microfluidic chips and assays necessary for high-throughput analysis. Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics plays a critical role in advancing precision medicine, drug discovery, and disease understanding through its innovative single cell and spatial biology technologies.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $643M | $444M | -$61M | -$44M | — |
| 2024 | $611M | $414M | -$195M | -$183M | — |
| 2023 | $619M | $409M | -$265M | -$255M | — |
| 2022 | $516M | $396M | -$168M | -$166M | — |
| 2021 | $490M | $416M | -$52M | -$58M | — |
| 2020 | $299M | $240M | -$534M | -$543M | — |
| 2019 | $246M | $185M | -$31M | -$31M | — |
| 2018 | $146M | $118M | -$111M | -$112M | — |
| 2017 | $71M | $61M | -$18M | -$19M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $1.04B | $245M | $796M | — | — |
| 2024 | $919M | $209M | $710M | $344M | — |
| 2023 | $965M | $224M | $741M | $359M | — |
| 2022 | $1.03B | $223M | $806M | $220M | — |
| 2021 | $1.02B | $201M | $818M | $587M | — |
| 2020 | $929M | $190M | $739M | $664M | — |
| 2019 | $606M | $186M | $420M | $424M | $30M |
| 2018 | $124M | $101M | -$220M | $65M | $25M |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $136M | $6M | $130M |
| 2024 | $7M | $12M | -$6M |
| 2023 | -$15M | $49M | -$64M |
| 2022 | -$34M | $132M | -$165M |
| 2021 | -$21M | $101M | -$123M |
| 2020 | -$218M | $37M | -$255M |
| 2019 | $35M | $43M | -$8M |
| 2018 | -$76M | $6M | -$83M |
| 2017 | -$11M | $4M | -$14M |

Source: [CompaniesByCap](https://companiesbycap.com/company/TXG)